• P59 Measuring Health Inequality Aversion in Canada: An Equity-Efficiency Trade-Off Experiment

    Dec 1, 2024, 00:00

  • EE767 Budget Impact Analysis of Fecal Microbiota Transplantation in Recurrent or Refractory Clostridioides Difficile Infection in Taiwan

    Dec 1, 2024, 00:00

  • EE701 The Cost-Effectiveness of an AI-Based Population Wide Screening Programme of Primary Open-Angle Glaucoma in the Netherlands

    Dec 1, 2024, 00:00

  • EPH260 Cost of Treatment for Mucopolysaccharidosis IV-A in a Poor Population in Colombia

    Dec 1, 2024, 00:00

  • CO116 Naldemedine Without Rescue Laxatives Versus Either Laxatives or Naloxegol in the Treatment of Opioid Induced Constipation Among Adults With Chronic Non-Cancer Pain

    Dec 1, 2024, 00:00

  • HTA21 Evaluating Key Drivers for Patient Access and Pricing Trends in ATMPs Across Germany, France, and the UK

    Dec 1, 2024, 00:00

  • PT22 Evaluating Reimbursement Pathway of Digital Health Technologies (DHT) Across Five European Countries

    Dec 1, 2024, 00:00

  • EPH133 AI Using Real-Life Data, an Additional Diagnostic Tool for Doctors to Identify Patient at Very High Risk of Renal Failure

    Dec 1, 2024, 00:00

  • EE756 Cost-Utility Analysis of Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate for Maintenance Therapy in Patients With Moderate-to-Severe Uncontrolled Asthma in China

    Dec 1, 2024, 00:00

  • HPR89 Is China Becoming More Attractive to Manufacturers of Innovative Medicines? Insights From the Boao Medical Pilot Zone

    Dec 1, 2024, 00:00

  • HTA60 ASCO Value Framework and ESMO-Magnitude of Clinical Benefit Scale in the Incorporation of New Technologies: Case Study and Challenges in the Private Health Care System

    Dec 1, 2024, 00:00

  • HTA188 Evaluating the Impact of Benefit Reassessment Outcomes for Orphan Drugs Surpassing the Revenue Limit in Germany

    Dec 1, 2024, 00:00

  • HTA161 Systematic Review With Indirect Comparison of Efficacy and Safety of Dupilumab Versus Omalizumab for Severe Asthma With Allergic Phenotype

    Dec 1, 2024, 00:00

  • EE278 A Survey on Japanese Drug Pricing and Treatment Costs of Cancer Chemotherapy Drugs: The Case of Monoclonal Antibodies

    Dec 1, 2024, 00:00

  • HPR30 Implementation of a National Value-Based Insurance Drug Formulary in the Saudi Private Health Sector

    Dec 1, 2024, 00:00

  • EE699 The Benefit of Introducing Remimazolam for Procedural Sedation in Belgian Clinical Practice

    Dec 1, 2024, 00:00

  • EE479 Real-World Evidence of Healthcare Utilization and Costs for Type 1 Diabetes and Severe Hypoglycemia by Age in Germany

    Dec 1, 2024, 00:00

  • EE771 Cost-Effectiveness Analysis of Cefiderocol Versus Imipenem/Cilastatin for Treatment of Complicated Urinary Tract Infection in Hospitalized Patients Using ChatGPT and TreeAge

    Dec 1, 2024, 00:00

  • HPR11 The Horizon of Oncology: Estimating the Impact of New EU Regulation on Health Technology Assessment for 2025-2028

    Dec 1, 2024, 00:00

  • HPR234 Access to Orphan Medicines in Portugal

    Dec 1, 2024, 00:00

  • EPH177 A Multimodal Deep Neural Network for Early Prediction and Detection of Alzheimer's Disease Based on MRI Images and Clinical Information

    Dec 1, 2024, 00:00

  • CO26 Encorafenib Plus Binimetinib Versus Dabrafenib Plus Trametinib in First-Line for Patients With Metastatic Non-Small Cell Lung Cancer Harboring BRAF V600E Mutation: Matching Adjusted Indirect Comparison of Pharos and BRF113928

    Dec 1, 2024, 00:00

  • HTA97 Impact of EMA's Conditional Marketing Authorizations on the Benefit Assessment Validity Period in Germany: Insights From 2017-2023

    Dec 1, 2024, 00:00

  • EE805 The Hazards of Applying Hazard Ratios to Accelerated Failure Time Models: A Simulation Study

    Dec 1, 2024, 00:00

  • EE677 Consolidating Methods of Cost-Utility Analysis for Newborn Screening of Spinal Muscular Atrophy: A Systematic Review

    Dec 1, 2024, 00:00

  • EE289 Cost of Hepatocellular Carcinoma in Türkiye: Results of a Delphi Panel Analysis

    Dec 1, 2024, 00:00

  • EE361 Long-Term Remission (LTR) Assumptions in Health Technology Assessments (HTAs) of Bispecific Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Following Two or More Lines of Systemic Therapy (3L+)

    Dec 1, 2024, 00:00

  • EE419 Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems

    Dec 1, 2024, 00:00

  • PT21 Promoting Access to Innovative Drugs: A Review of National Drug Price Negotiation in China

    Dec 1, 2024, 00:00

  • EE655 Cost-Effectiveness Analysis of Eladocagene Exuparvovec for the Treatment of Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd) From a United States (US) Perspective

    Dec 1, 2024, 00:00

  • EPH253 Retrospective Study of Treatment Patterns and Patient Characteristics of Patients With Prostate Cancer Treatment in Germany According to Castration Resistance and Metastatic Status

    Dec 1, 2024, 00:00

  • HSD27 Implementing Outcome Measurement for Lung Cancer Patients at an Oncology Center

    Dec 1, 2024, 00:00

  • EE812 Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for Mild-to-Moderate and Moderate-to-Severe Alzheimer's Disease Patients in USA

    Dec 1, 2024, 00:00

  • EE499 Health Resource Utilization (HRU) and Costs of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) in the United States (US): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE501 Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY

    Dec 1, 2024, 00:00

  • EE376 Rheumatoid Arthritis, Cost-Effectiveness Analysis of Biosimilar Tocilizumab in Spain

    Dec 1, 2024, 00:00

  • HPR134 Impact of Loss of Exclusivity on the Expenditure of Medicines: An Analysis on Molecules for Which a Generic or Biosimilar Was Introduced in the Netherlands After 2012

    Dec 1, 2024, 00:00

  • HSD5 Real-World Survey on Treatment Pathways and Patterns for Patients With Primary Immune Complex Membranoproliferative Glomerulonephritis

    Dec 1, 2024, 00:00

  • HPR40 Determinants of the Prices of Orphan Drugs in France

    Dec 1, 2024, 00:00

  • EE788 Predicting Health Spending by Risk Level and Severity in a Colombian Health Promotion Entity

    Dec 1, 2024, 00:00

  • EE326 Cost-Effectiveness of Spleen Aminopeptide Oral Solution in the Treatment of Adenoid Hypertrophy in Children

    Dec 1, 2024, 00:00

  • Editor Message

    Dec 1, 2024, 00:00

  • CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EPH277 Prevalence, Management, and Comorbid Condition Trends for Obesity Within US Self-Insured Employers

    Dec 1, 2024, 00:00

  • EE760 Is There a Place for First-Generation mRNA Seasonal Influenza Vaccines? Unraveling the Clinical and Economic Consequences of Increased Reactogenicity in U.S. Older Adults

    Dec 1, 2024, 00:00

  • HTA47 The Difference Between PICO Evaluation Across Australia, EU4, and UK

    Dec 1, 2024, 00:00

  • HTA98 Patient Consensus on PICO Scoping for the Health Technology Assessment (HTA) Regulation: A Case for Delphi Methodology

    Dec 1, 2024, 00:00

  • EE382 Cost of Implementing Alectinib as an Adjuvant Treatment for ALK+ Non-Small Cell Lung Cancer in Denmark (C-ALINA)

    Dec 1, 2024, 00:00

  • EE541 Cost-Effectiveness Analyses of Acute Ischemic Stroke Care Pathways: A Model for Different Scenarios and Countries

    Dec 1, 2024, 00:00

  • HPR182 Innovative Contracts: A Solution to Manage the ATMPs Associated Uncertainty

    Dec 1, 2024, 00:00

  • HPR38 Top Trends Affecting the Vaccines Market and Their Implications on Access Policy and Public Health Decision-Making

    Dec 1, 2024, 00:00

  • EE558 Economic Evaluations of Treatments for Acquired Hemophilia: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE338 Cost-Effectiveness of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis Versus Current Use of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine or No PrEP to Prevent HIV-1 in Individuals at High Risk in Spain

    Dec 1, 2024, 00:00

  • EE599 Estimating the Potential Lifetime Health and Economic Impact of V116 on Pneumococcal Disease in Mexico

    Dec 1, 2024, 00:00

  • HSD22 Perceptions of Physicians on the Diagnosis of Rare Diseases in Europe: Results of a Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • HTA194 Overview of NICE Cost-Comparison Technology Appraisals: Key Takeaways Regarding Comparator Selection and Methods Used to Demonstrate Comparable Efficacy

    Dec 1, 2024, 00:00

  • HPR224 Utilization of Long-Term Care Before and After the 2015 Dutch National Reform: An Interrupted Time Series Analysis

    Dec 1, 2024, 00:00

  • HTA167 Use of Real-World Evidence in Health Technology Reassessments Across Six Health Technology Assessment Agencies

    Dec 1, 2024, 00:00

  • EE671 Guidance for the Economic Evaluation of Prognostic and Predictive Companion Diagnostics: A Systematic Scoping Review

    Dec 1, 2024, 00:00

  • EE750 Cell-Based Therapies Reduce Costs and Knee Replacement Surgeries and Increase QALYs Among Knee Osteoarthritis Patients in the Netherlands: A Cost-Effectiveness Study

    Dec 1, 2024, 00:00

  • HTA210 Effectiveness of Generic Quality of Life (QoL) Questionnaires in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2024, 00:00

  • CO75 A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia

    Dec 1, 2024, 00:00

  • EPH271 Dementia Awareness and Risk Factors Assessment: A Cross-Sectional Study of the Irish Population

    Dec 1, 2024, 00:00

  • HPR85 Socioeconomic Impact of Reverse Switching Over-the-Counter (OTC) Antifungal and Antiviral Medicines to Prescription Only Medicines (POM)

    Dec 1, 2024, 00:00

  • CO53 The Impact of Approved Anti-Obesity Medications on the Risk of Obstructive Sleep Apnea in Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE611 Cost-Effectiveness of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia

    Dec 1, 2024, 00:00

  • HTA58 Methods Used to Adjust for Cross-Over in Clinical Trials: Insights From Scandinavian Health Technology Assessments

    Dec 1, 2024, 00:00

  • EE299 Economic Burden of Cardiovascular Diseases in Indonesia: Analysis of BPJS Kesehatan National Health Insurance Claims Data 2021-2022

    Dec 1, 2024, 00:00

  • EPH175 Baseline Risk of Hospitalization and Death in a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • HPR123 Assessment of Price Reduction Prediction Based on the Lasted Reimbursement Drug Renewal Rules in China

    Dec 1, 2024, 00:00

  • EE731 Ropeginterferon Alfa-2B Is Cost-Effective to Manage Low-Risk Patients With Polycythemia Vera As Compared to Phlebotomy Only

    Dec 1, 2024, 00:00

  • EPH154 Long-Term Incident Heart Failure After Acute Coronary Syndrome: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • HPR219 Studies on Health Economics and Outcomes From Türkiye Published in ISPOR by the Year 2024

    Dec 1, 2024, 00:00

  • EE630 Effects and Costs of Country-Level Hepatitis C Virus Elimination in China: A Modelling Study

    Dec 1, 2024, 00:00

  • EPH229 Regional Differences in Morbidity Across Germany: A Cross-State Comparison Using Hospital Data

    Dec 1, 2024, 00:00

  • EPH134 Home Sweet Hospital: Evaluating Evidence Gaps and Future Research Priorities for Hospital at Home

    Dec 1, 2024, 00:00

  • EE256 Darolutamide As a Leading Option to Manage Prostate Cancer

    Dec 1, 2024, 00:00

  • EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales

    Dec 1, 2024, 00:00

  • EPH126 Assessment of the Effects of Metabolism of Caffeine on Reaction Time by Age Group

    Dec 1, 2024, 00:00

  • CO109 Evaluating the Psychometric Properties of the Brazilian Portuguese EQ Health and Well-Being Short Form (EQ-HWB-S)

    Dec 1, 2024, 00:00

  • HTA13 Is Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions

    Dec 1, 2024, 00:00

  • EPH276 Predicting the Public Health Impact of Different Adult Pneumococcal Vaccines in Japan Using a Dynamic Transmission Model

    Dec 1, 2024, 00:00

  • EPH148 Medical Costs of Adults With COVID-19 in Guatemala During the Endemic Phase: A Micro-Costing Study

    Dec 1, 2024, 00:00

  • EE746 Budget and Organizational Impact Models (OBIM) for Health Products in Europe: An Overview from 2014 to 2024

    Dec 1, 2024, 00:00

  • HPR70 Distribution of Prescriptions From Medical Institutions to Pharmacies in Japan: An Analysis of Health Insurance Claims Database

    Dec 1, 2024, 00:00

  • HPR242 Lump-Sum Envelopes: High Predictability for Payers (Healthcare Product Pricing Committee – CEPS) and Minor Contribution for Companies

    Dec 1, 2024, 00:00

  • EE729 Clinical and Economic Impact of a Tri-Layer Hybrid Biomaterial vs Synthetic Mesh for Ventral Hernia Repair in Australia: A Cost-Consequence and Budget Impact Analysis

    Dec 1, 2024, 00:00

  • EE262 Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective

    Dec 1, 2024, 00:00

  • EPH138 Identifying and Profiling Patients With Heart Failure in a Population-Based Cohort Through Linkage of Primary and Secondary Care Data

    Dec 1, 2024, 00:00

  • EE651 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Low-Grade Glioma Requiring Systemic Treatment in England and Wales

    Dec 1, 2024, 00:00

  • EE766 Burden of HPV-Related Diseases in the Czech Republic: Model-Based Study

    Dec 1, 2024, 00:00

  • Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists

    Dec 1, 2024, 00:00

  • HSD132 An Integral Approach to Assess the 3 Human Normal Immunoglobulin Formulations for Primary Immunodeficiency in Portugal: Combining Costs, Patient's Preferences, and HCP Choices

    Dec 1, 2024, 00:00

  • CO46 Cognitive Assessments in Drug Development in Dementia and MCI: Clinical Trial Landscape Review and Recommendations for Future Neurodegenerative Studies

    Dec 1, 2024, 00:00

  • EE293 Cost-Effectiveness of Diagnostic Testing for Hepatitis Delta in the United Kingdom

    Dec 1, 2024, 00:00

  • HPR52 Macroeconomic Regulation of Drug Expenditures in Europe: Lessons for the French Safeguard Clause From a Scoping Review

    Dec 1, 2024, 00:00

  • HTA9 Cross Analysis of HAS Conclusions Amongst Products With an Economic Opinion Posted in 2023

    Dec 1, 2024, 00:00

  • HTA50 Characterizing Evidentiary Critiques in HTA Decision-Making for Treatments Indicated for Overweight and Obesity

    Dec 1, 2024, 00:00

  • EPH147 Situational Analysis of Sexual Health in Cartagena and Bolívar, Colombia 2023

    Dec 1, 2024, 00:00

  • HTA226 Lack of Face Validity in Health Technology Assessments: Systematic Review of NICE Assessments and Lessons Learned

    Dec 1, 2024, 00:00

  • EE557 A Systematic Review of Productivity Gain/Loss in Health Economic Evaluations: An Element for Value Assessment of Innovative Treatments

    Dec 1, 2024, 00:00

  • EE663 Budget Impact Analysis of Fracture Risk Assessment (FRAX) Based Treatment Strategy Selection in Patients With Glucocorticoid-Induced Osteoporosis (GIOP)

    Dec 1, 2024, 00:00

  • EE267 Cost Effectiveness and Budget Impact of the Recombinant Zoster Vaccine Among Older Adults in Singapore

    Dec 1, 2024, 00:00

  • EE301 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Lenvatinib for the Treatment of Advanced Second-Line Endometrial Cancer

    Dec 1, 2024, 00:00

  • EPH207 Incidence and Prevalence of Idiopathic Pulmonary Fibrosis (IPF): A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EE656 Challenges in Health-Economic Modeling of Phenylketonuria (PKU): A Targeted Review of HTA Evaluations

    Dec 1, 2024, 00:00

  • EE253 Health Care Visits and Out-of-Pocket Costs in People With Chronic Hand Eczema

    Dec 1, 2024, 00:00

  • HTA184 Uncertainty Appraisal in Economic Opinions of the French National Authority for Health

    Dec 1, 2024, 00:00

  • HTA142 Use of External Control Arms in Reimbursement Submissions: A Review of CAR-T Appraisals by NICE and CDA

    Dec 1, 2024, 00:00

  • HSD120 Evaluating Pre-Treatment Patient Pathways in Early Alzheimer's Disease Management: A Claims Data Analysis in Germany

    Dec 1, 2024, 00:00

  • HSD103 Scoping Review on Attitudes and Barriers Towards Therapeutic Drug Monitoring for Biological Treatments for Immune-Mediated Inflammatory Diseases Among Key Stakeholders

    Dec 1, 2024, 00:00

  • CO27 Comparative Effectiveness of the mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Canadians: A Systematic Literature Review and Meta-Analysis Using the Grade Framework

    Dec 1, 2024, 00:00

  • EE495 Cost-Effectiveness of a Comprehensive HBV Screening and Management Program in China: A Real-World Data Analysis From Huazhou City

    Dec 1, 2024, 00:00

  • P6 Projected Increase of the Clinical, Economic, Societal, and Environmental Burdens of Chronic Kidney Disease in Switzerland: Insights from Impact-CKD

    Dec 1, 2024, 00:00

  • EE429 Insights From an Expert Advisory Board: The Trends Driving Changes in Managed Care

    Dec 1, 2024, 00:00

  • EE755 Substantial Healthcare Resource Utilization in Patients Diagnosed With Viral Lower Respiratory Tract Disease in Spain

    Dec 1, 2024, 00:00

  • P4 Bias Reduction in Indirect Treatment Comparison of Time-to-Event Outcomes: A Case Study on Application of ML-NMR Versus MAIC Using Simulated Dataset

    Dec 1, 2024, 00:00

  • EE496 Relugolix/Estradiol/Norethisterone Compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40 YEAR Old): A Cost-Utility Analysis

    Dec 1, 2024, 00:00

  • EPH139 Prevalence and Disease Burden of Disease-Related Malnutrition in Hospitalized Patients in Spain

    Dec 1, 2024, 00:00

  • HTA106 How Has Treatment Switching Been Accounted for? Insights From NICE Appraisals

    Dec 1, 2024, 00:00

  • HSD91 Integrated Care Process and Pharmacological Prescription for Patients With Hypercholesterolemia or Mixed Dyslipidemia at High or Very High Cardiovascular Risk in Catalonia

    Dec 1, 2024, 00:00

  • HTA179 A Targeted Review of Treatment Beyond Progression in NICE HTA Oncology Submissions

    Dec 1, 2024, 00:00

  • EPH70 Association Between Sleep Disorders and Subsequent Depression in Children and Adolescents: A Retrospective Cohort Study With 62,796 Patients in Germany

    Dec 1, 2024, 00:00

  • EPH61 Sex-Related Disparities in Chronic Cough Reported by Adults in the United States

    Dec 1, 2024, 00:00

  • HTA189 Alignment of EU HTA and Member State Clinical Assessments and the Potential Impact on Value Perception

    Dec 1, 2024, 00:00

  • EE649 Prerequisites for Cost-Effective Home Blood Pressure Telemonitoring: Insights From an Early Health Economic Analysis

    Dec 1, 2024, 00:00

  • EE819 How Can Discrete Choice Experiment Method Improve Patient Care and Engagement? An Example in the Field of Fertility

    Dec 1, 2024, 00:00

  • HPR127 The Cost Effectiveness of Collaborative Dementia Care for Alzheimer's Disease Relative to Disease Modifying Therapies

    Dec 1, 2024, 00:00

  • EE426 Cost-Effectiveness of Switching From PCV13 to PCV20 in the Portuguese Childhood National Immunization Program

    Dec 1, 2024, 00:00

  • EPH239 Positive Airway Pressure (PAP) Therapy in Obstructive Sleep Apnea (OSA): Modeling of 20 Year Mortality and Hospitalizations

    Dec 1, 2024, 00:00

  • HSD97 Clinicopathological Features Associated With the High Risk of Recurrence of Stage II Colorectal Cancer: Variability Among Guidelines and Studies, and Potential Implications for Market Access

    Dec 1, 2024, 00:00

  • EE308 The Economic Burden of Alcohol in Belgium: Incremental Healthcare and Indirect Costs

    Dec 1, 2024, 00:00

  • CO52 Relationship Between Hemoglobin Levels and EQ-5D-5L Utility Index in Patients With Cold Agglutinin Disease

    Dec 1, 2024, 00:00

  • CO82 Long-Acting Somatostatin Analogues Treatment Patterns and Outcomes in Neuroendocrine Tumor Patients: An Italian Propensity Score Matched Cohort Study

    Dec 1, 2024, 00:00

  • HTA134 Implications of Indication Expansions on Pricing and Reimbursement and How This Differs Between EU4 and UK Markets

    Dec 1, 2024, 00:00

  • HPR117 The Economic Burden of Lung Cancer in Gree A Systematic Review of the Literature

    Dec 1, 2024, 00:00

  • PT7 Reassessment Dynamics of Orphan Drugs in Germany’s Benefit Assessment Process

    Dec 1, 2024, 00:00

  • HTA227 Evaluating the Importance of Patient Input in NICE Highly Specialized Technology (HST) Assessments: Insights From Review Reports

    Dec 1, 2024, 00:00

  • EE280 Impact of COVID-19 on Healthcare Utilization and Costs: A Detailed Analysis From Inpatient and Outpatient Perspectives

    Dec 1, 2024, 00:00

  • HPR160 Integrating Healthcare System Value Into New Medicine Evaluations for Timely and Full Patient Access

    Dec 1, 2024, 00:00

  • PT27 Time to Reimbursement in Ireland: Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines

    Dec 1, 2024, 00:00

  • Disclaimer

    Dec 1, 2024, 00:00

  • HPR29 Impact of Diagnosis-Related Groups (DRG) Payment on the Quality and Efficiency of Peripheral Arterial Disease (PAD) Care: A Mixed-Methods Study

    Dec 1, 2024, 00:00

  • P50 Technical Validation of an Environmental Model of Aurora EV-ICD: Recommendations to Guide Environmental Criteria in Health Technology Assessment

    Dec 1, 2024, 00:00

  • EE271 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine for Adults 60 Years or Older in Austria

    Dec 1, 2024, 00:00

  • HTA185 From Plan to Action: Assessing the Impact of the NICE Real-World Evidence Framework Following Its Introduction in June 2022

    Dec 1, 2024, 00:00

  • EPH110 Trends in Epidemiology and Mortality of Patients With Colorectal Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HSD44 Physical Therapy in Patients With Pulmonary Arterial Hypertension (PAH): Results From a German Claims Data Analysis

    Dec 1, 2024, 00:00

  • EPH23 The Use of Machine Learning Techniques for Healthcare Cost Prediction: A Preliminary Analysis of Administrative Databases From a Health Protection Agency in Northern Italy

    Dec 1, 2024, 00:00

  • EE652 Budget Impact of Lecanemab for Alzheimer's Disease Patients Among Medicare Beneficiaries in the United States: A Subgroup Analysis

    Dec 1, 2024, 00:00

  • HPR21 The Impact of the Health Act (Pricing and Supply of Medical Goods) (2013) on the Pricing of Medicines in Ireland

    Dec 1, 2024, 00:00

  • EE707 In-Office Versus Operating Room Hysteroscopic Resection of Endometrial Polyps: A Cost Analysis From a Spanish Hospital Perspective

    Dec 1, 2024, 00:00

  • EE303 Adult Immunization With Tetanus, Diphtheria, and Pertussis Vaccine for at-Risk Populations (Asthma, COPD, HIV) for the Prevention of Pertussis in Colombia

    Dec 1, 2024, 00:00

  • EE477 A Budget Impact Analysis of Introducing Filgotinib for the Treatment of Rheumatoid Arthritis in Greece

    Dec 1, 2024, 00:00

  • HPR25 Assessing Sustainable Biosimilar Competition: Current Trends and Impacts of Anti-TNF Biosimilar Competition in Europe

    Dec 1, 2024, 00:00

  • EPH8 Risk of Acute Pancreatitis Associated With ARBs and ACE Inhibitors: A Meta-Analysis of Observational Studies

    Dec 1, 2024, 00:00

  • EPH40 Challenges and Issues of Patients Living With HIV in Algeria: Current Epidemiological Situation

    Dec 1, 2024, 00:00

  • HSD137 The Value Proposition of Remote Monitoring in Heart Failure: Pains and Gains Towards Patients’ Adoption

    Dec 1, 2024, 00:00

  • EPH257 Impact of Fragility Fractures in the Bolívar Department, Colombia

    Dec 1, 2024, 00:00

  • HPR14 The Landscape of Approved Drugs With Pediatric Orphan Indications in Saudi Arabia

    Dec 1, 2024, 00:00

  • EE275 Real-World Healthcare Resource Utilization and Costs in Patients With Locally Advanced or Metastatic Urothelial Carcinoma in China

    Dec 1, 2024, 00:00

  • P13 Development of a Goal Attainment Scale (GAS) and Global Impression (GI) Items for Use As Outcome Measures in Intervention Studies in Pediatric Autism

    Dec 1, 2024, 00:00

  • EE474 Valuation and Exploitation of Sick Leaves Identified in the French SNDS Database

    Dec 1, 2024, 00:00

  • EE837 Cost Effectiveness of Nirsevimab and Maternal RSVpreF Vaccine for Prevention of Respiratory Syncytial Virus Disease Among Infants in the United States

    Dec 1, 2024, 00:00

  • Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany

    Dec 1, 2024, 00:00

  • EE337 Cost-Effectiveness of [177Lu]Lu-PSMA-617 in Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2024, 00:00

  • HPR238 FDA vs EMA a Comparison of New Chemical Entity Approvals: The Role of Start-Ups

    Dec 1, 2024, 00:00

  • EE568 Economic Evaluation of the Co-Formulated Antiretroviral Efavirenz 400mg/Lamivudine/Tenofovir Disoproxil Fumarate for the Treatment of HIV-1 Infection in Adult Patients From the Perspective of the Mexican Public Health System

    Dec 1, 2024, 00:00

  • EPH246 Comparison of Approval Dates of New Medications Between Europe (European Medicines Agency, EMA), Japan (Pharmaceutical and Medical Devices Agency, PMDA), and the United States (US) of America (Food and Drug Administration, FDA)

    Dec 1, 2024, 00:00

  • EE240 Evaluating the Impact of Matched-Adjusted Indirect Comparisons on Propagated Uncertainty in Economic Outcomes

    Dec 1, 2024, 00:00

  • CO120 Assessment of Metformin Failure Among Patients With Type 2 Diabetes Mellitus at a Tertiary Care Center in Central India

    Dec 1, 2024, 00:00

  • EPH158 Assessing the Public Health Benefit of a mRNA-Based Respiratory Syncytial Virus Vaccine (mRNA-1345) Among Adults ≥65 Years in France

    Dec 1, 2024, 00:00

  • HTA112 Can Excess Hazard Models Enhance Survival Analysis in Health Technology Assessments?

    Dec 1, 2024, 00:00

  • EE442 Cost-Utility Analysis and Efficiency Frontier Approach of Tafasitamab in Brazilian Private Healthcare System Perspective

    Dec 1, 2024, 00:00

  • EE759 Cost-Effectiveness of Tezepelumab in Taiwan for Severe Asthma

    Dec 1, 2024, 00:00

  • EE695 Applying NICE's Disease Severity Modifier to the Context of Cancer Screening

    Dec 1, 2024, 00:00

  • EPH127 Drivers and Consequences of Plasma-Derived Medicinal Product Shortages

    Dec 1, 2024, 00:00

  • HTA137 The Changing Landscape of Health Technology Assessment (HTA) in the Asia-Pacific (APAC) Region: Advances, Challenges, and Future Goals

    Dec 1, 2024, 00:00

  • HPR153 Analysis of Annual-Cost Threshold for Drugs Reimbursement Decisions in China

    Dec 1, 2024, 00:00

  • EPH135 Real-World Prescribing Patterns of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Germany

    Dec 1, 2024, 00:00

  • HPR236 Assessing the Reimbursement Landscape of Oncology Products in the Turkish Pharmaceutical Market

    Dec 1, 2024, 00:00

  • HTA165 A Comparative Analysis of Reimbursement Outcomes for Orphan Drugs Between EU and Non-EU Countries

    Dec 1, 2024, 00:00

  • EE636 Evaluating the Potential Health and Economic Impact of V116, an Adult Specific 21-Valent Pneumococcal Conjugate Vaccine, on Invasive Pneumococcal Disease in Spain

    Dec 1, 2024, 00:00

  • EE244 Economic Burden of Grade 3+ Adverse Event Management Associated With Dato-DXd and Docetaxel-Containing Regimens in Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: A European and USA Analysis

    Dec 1, 2024, 00:00

  • HSD38 Continuity of Medication Care for Cancer Patients Through Outpatient Service Provision in Specialist Practices in Germany

    Dec 1, 2024, 00:00

  • EE518 Economic Evaluations of Anifrolumab for the Management of Patients Affected by Systemic Lupus Erythematosus (SLE) in Italy

    Dec 1, 2024, 00:00

  • HTA158 A Comprehensive Review of NICE Highly Specialized Technology Appraisals

    Dec 1, 2024, 00:00

  • EE717 Influence on Antibiotic Prescribing and Cost Effects Through Standardized Implementation of PoC Testing in Adults With Sore Throats in Standard SHI Care

    Dec 1, 2024, 00:00

  • EE507 Deriving Decision Uncertainty Associated With Calibration Target Data: A Value of Information Approach

    Dec 1, 2024, 00:00

  • EE506 Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica

    Dec 1, 2024, 00:00

  • EPH31 Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)

    Dec 1, 2024, 00:00

  • EE525 Exploring the Implementation of Polygenic Risk Scoring in Alzheimer's Disease: An Early Value Model

    Dec 1, 2024, 00:00

  • CO133 Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients With Obesity: A Bayesian Network Meta-Analysis of GLP-1 RCTs

    Dec 1, 2024, 00:00

  • EPH159 Estimating the Remaining Chronic HCV Prevalence in Ireland: A Risk Population Modelled Approach Applied in Practice

    Dec 1, 2024, 00:00

  • HPR207 How Long Is Long Enough? Data Collection Duration for Medicines in Managed Access in England

    Dec 1, 2024, 00:00

  • HPR185 Performance-Based vs Finance-Based Managed Entry Agreements (MEAs): Global Trends and Challenges

    Dec 1, 2024, 00:00

  • EE500 Global Economic Burden of Retinitis Pigmentosa (RP): A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE597 Budget Impact Analysis of Introducing Benralizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: A European Perspective

    Dec 1, 2024, 00:00

  • EE527 Economic Evaluation of Using Romiplostim for Early Immune Thrombocytopenia in Qatar

    Dec 1, 2024, 00:00

  • CO36 Placebo Effect for Clinical Remission in Induction and Maintenance Treatment in Crohn's Disease: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • Exploring the Association Between Surgical Out-of-Pocket Costs and Healthcare Quality Outcomes: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • P42 EQ-5D-5L Mapping Function Recently Recommended by NICE Is Likely to Generate Higher Utility Values

    Dec 1, 2024, 00:00

  • HTA54 Review of Cell and Gene Therapies by NICE, HAS, and G-BA: How Did They Fare?

    Dec 1, 2024, 00:00

  • HPR151 Analysis of the Outcomes of the Hearings of the Transparency Committee in France

    Dec 1, 2024, 00:00

  • EE551 Cost-Minimization of Faricimab Vs Aflibercept 8 Mg in Patients With Neovascular Age-Related Macular Degeneration (nAMD): Evaluating the Impact of Retreatment Criteria

    Dec 1, 2024, 00:00

  • EE840 Assessing Direct Medical Costs of Stage IV NSCLC in Iraq From Public Payer Perspective

    Dec 1, 2024, 00:00

  • PT25 Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer

    Dec 1, 2024, 00:00

  • HPR78 Opportunities and Barriers for the Implementation of the Personalized Medicine in Lithuania

    Dec 1, 2024, 00:00

  • EPH214 Epidemiological Disparities and Risk Factors of Esophageal Cancer in Türkiye: A Systematic Review

    Dec 1, 2024, 00:00

  • EE552 Cost-Effectiveness of a Large Language Model for Indexing Biomedical Abstracts

    Dec 1, 2024, 00:00

  • HSD76 Treatment Utilization and Treatment Duration of Patients With Psoriasis Diagnosed With Psoriatic Arthritis in a US Commercial Administrative Claims Database

    Dec 1, 2024, 00:00

  • HPR126 Health Economics Centers and Support in SUS Management: A Report of Successful Experiences

    Dec 1, 2024, 00:00

  • HPR214 Use of Multicriteria Decision Analysis (MCDA) for Includes Innovation in Public Health Policy Formulation: A Scoping Review

    Dec 1, 2024, 00:00

  • EE329 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-23 Targeted Therapies for Psoriatic Arthritis in Spain, Based on Matching-Adjusted Indirect Comparisons

    Dec 1, 2024, 00:00

  • HTA203 Dynamic Vaccine Valuation: A Method Framework for Early Health Technology Assessment, Driving Innovation, and Implementation Strategies

    Dec 1, 2024, 00:00

  • CO96 Anti-Obesity Medications and Related Osteoarthritis Risk Among Patients With Obesity

    Dec 1, 2024, 00:00

  • EPH39 Economic Implications of Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patient Characteristics, Unmet Needs, and Cost-Effectiveness

    Dec 1, 2024, 00:00

  • EPH185 How Digital Tools Support a Sustainable Supply Chain in Healthcare: A Scoping Review on the Status Quo of Circular Economy

    Dec 1, 2024, 00:00

  • EE824 Are Standard Economic Evaluations Suitable for Evaluating Life-Extending Innovations in Kidney Care?

    Dec 1, 2024, 00:00

  • EE823 The Impact of Weight Loss in a Japanese Cohort of Individuals Living with Obesity

    Dec 1, 2024, 00:00

  • HSD30 Hospital Methodology for Steering on Patient Value: Healthcare Outcomes in Relation to Costs

    Dec 1, 2024, 00:00

  • HPR119 Resolving the Difficulties of External Reference Pricing in Medical Devices Towards Equitable Pricing

    Dec 1, 2024, 00:00

  • Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

    Dec 1, 2024, 00:00

  • HSD55 Impact of a Novel Bone Health Dedicated Outpatient Clinics for Managing Cancer Treatment-Induced Bone Loss: A Propensity-Score Matching Study

    Dec 1, 2024, 00:00

  • HTA166 Beyond RCTs: The Role of Real-World Evidence in NICE Submissions for Rare Diseases

    Dec 1, 2024, 00:00

  • CO114 A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated With Treatments for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Progressed on Prior Therapies

    Dec 1, 2024, 00:00

  • EPH183 Utilization and Expenditure on Medicines for the Prevention and Treatment of Osteoporosis: A Changing Landscape

    Dec 1, 2024, 00:00

  • CO33 Payer-Reported Unmet Need Burden Post Allogeneic Hematopoietic Cell Transplantation (HCT) Due to Poor Graft Function (PGF) and Characteristics of an Ideal Treatment for PGF

    Dec 1, 2024, 00:00

  • EE592 Performance Evaluation of Explainable Artificial Intelligence to Replicate a Systematic Review and Meta-Analysis of Cost-Effectiveness Analysis Findings

    Dec 1, 2024, 00:00

  • HTA76 Approaches and Challenges in the Rapid Estimation of Quality-Adjusted Life Expectancy Shortfalls Based on Published Kaplan-Meier Curves and Utility Values

    Dec 1, 2024, 00:00

  • HSD95 Economic Results of a Model for the Detection of Pharmacological Inefficiencies in Patients With Chronic Diseases

    Dec 1, 2024, 00:00

  • EPH141 Intersecting Challenges: Progressive Multifocal Leukoencephalopathy (PML) and Underlying Diseases

    Dec 1, 2024, 00:00

  • The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study

    Dec 1, 2024, 00:00

  • P53 Budget Impact Analysis of a Possible Extension of Public Funding for the Treatment of Disease-Related Malnutrition in Spain

    Dec 1, 2024, 00:00

  • EE632 Early Cost-Effectiveness of SPECTRISTM (Gamma Band Stimulation) in Mild-Moderate Alzheimer's Disease Patients

    Dec 1, 2024, 00:00

  • HTA213 Conceptual Approach for a Value-Based Assessment Tool in Oncology and Its Application in Advanced Triple Negative Breast Cancer in Colombia

    Dec 1, 2024, 00:00

  • HPR208 Does the Improvement of Medical Insurance Equity Enhance the Mental Health of Elderly Residents in Rural Areas? Evidence From the Adjustment of Medical Insurance Policy in China

    Dec 1, 2024, 00:00

  • EPH248 Age-Adjusted Years of Potential Life Lost (YPLL) Rates Due to Ovarian Cancer in Chile During 2002-2019

    Dec 1, 2024, 00:00

  • EPH251 Estimate of Brazilian Population in Secondary Prevention of Cardiovascular Disease in Public Healthcare System: Evaluating Potential Need for Lipid-Lowering Treatment Beyond Statin and Ezetimibe

    Dec 1, 2024, 00:00

  • EPH97 Characteristics of Cannabis-Based Consumer Health Products Users in Community Pharmacies in Portugal

    Dec 1, 2024, 00:00

  • Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom

    Dec 1, 2024, 00:00

  • P3 Multivariate Network Meta-Analysis Using Restored Accurate Within-Study Correlation Information: Application to Comparative Effectiveness Analysis of Biologics for Plaque Psoriasis

    Dec 1, 2024, 00:00

  • HTA230 Indirect Treatment Comparisons in NICE Highly Specialized Technology Assessments

    Dec 1, 2024, 00:00

  • HSD119 How a Government Policy Can Have a Positive Impact on Women's Choice of Contraception: A Study of Irish Pharmacy Sales Data Between the Years 2021-2024

    Dec 1, 2024, 00:00

  • EE778 Early Cost-Consequence Analysis of Comprehensive Genomic Profiling in a Metastasized Tumor-Agnostic Population

    Dec 1, 2024, 00:00

  • EPH107 Leveraging Primary Care Patient Data to Investigate the Epidemiology of Systemic Lupus Erythematosus in Italy

    Dec 1, 2024, 00:00

  • HSD84 Towards a Frictionless CAR-T Therapy Process: Identifying and Prioritizing Procedural Preconditions for Oncologic Institutions Using Group Concept Mapping

    Dec 1, 2024, 00:00

  • EE409 The Economic Impact of Early Comprehensive Genomic Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer Patients: Real World Evidence From a Brazilian Private Healthcare Provider Database

    Dec 1, 2024, 00:00

  • HPR177 Modeled Impact of Risk-Sharing Agreements on Costs for Hemophilia B Gene Therapy in Germany

    Dec 1, 2024, 00:00

  • CO7 Progression-Free Survival As a Surrogate for Overall Survival in Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EPH10 Dynamics of Self-Medication Among Expectant Mothers in a City in Southeast Nigeria

    Dec 1, 2024, 00:00

  • EE560 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Versus Traditional Method for the Prevention of Incontinence-Associated Dermatitis in a Hospital Setting in New Zealand

    Dec 1, 2024, 00:00

  • EPH37 Adult Vaccinations in Europe: Unfulfilled Potential

    Dec 1, 2024, 00:00

  • EE522 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab in Adolescents With Severe Atopic Dermatitis in Spain

    Dec 1, 2024, 00:00

  • EE355 The Impact of Dynamic Mortality on the Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in France

    Dec 1, 2024, 00:00

  • EE237 Cost-Minimization Analysis for Soliqua in the Treatment of T2DM in Turkiye

    Dec 1, 2024, 00:00

  • EE722 Assessing Healthcare Resource Use and Burden Among an Older Population of Patients With Respiratory Syncytial Virus in Five European Countries Using Real-World Data

    Dec 1, 2024, 00:00

  • HTA42 Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines (2021-2022)

    Dec 1, 2024, 00:00

  • EPH161 Psychiatric Multimorbidity and Risk of Dementia: A 23-Year Cohort Study Using Akrivia Health Secondary Mental Healthcare Data

    Dec 1, 2024, 00:00

  • HSD24 Estimating the Global and EU27+UK Prevalence of Patients With Cancer in Palliative Care and Patients in Two Neurodegenerative Disorders Potentially Benefiting From Cannabinoid-Based Medicines

    Dec 1, 2024, 00:00

  • EPH130 The Humanistic Burden and Productivity Lost From Atopic Dermatitis in Central and Eastern European Countries

    Dec 1, 2024, 00:00

  • EE363 Use of Artificial Intelligence in Stress Echocardiography in NHS Coronary Artery Disease Risk Prediction: A Cost Effectiveness Analysis Study

    Dec 1, 2024, 00:00

  • HTA59 Assessing Efficiencies of AI-Powered Tools in Reporting Healthcare Economics and Outcomes Research (HEOR) Data for Health Technology Assessment (HTA) Submissions

    Dec 1, 2024, 00:00

  • CO78 High-Efficacy Therapies (HETs) First Versus an Escalation Approach in Multiple Sclerosis: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EE757 Cost-Effectiveness of DNA Methylation as Triage for Cervical Cancer Screening in Hong Kong: A Modelling Study

    Dec 1, 2024, 00:00

  • HSD11 Patient Journey Mapping of the Gene Therapy in Hemophilia B in Spain: The Bhemogen Project

    Dec 1, 2024, 00:00

  • EE783 Cost-Effectiveness Analysis of an Advanced Hybrid Closed Loop System Versus Standard of Care in the Management of Type 1 Diabetes in the Netherlands

    Dec 1, 2024, 00:00

  • EE403 The Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in Germany

    Dec 1, 2024, 00:00

  • EE528 Cost-Effectiveness Analysis of the TAK-003 Dengue Vaccine Introduction in Argentina

    Dec 1, 2024, 00:00

  • HPR140 Using Safety Engineered Intravenous Access Devices in Malaysia to Reduce Needle Stick Injuries: A Meta-Analytic Synthesis of Literature Health System Projection

    Dec 1, 2024, 00:00

  • HTA183 A General Framework for Early Health Technology Assessment (eHTA) to Support the Development of New Radiology Artificial Intelligence (AI) Tools

    Dec 1, 2024, 00:00

  • HTA225 Optimizing HTA Outcomes in Cost-Effectiveness Markets: A Case Study of Axicabtagene Ciloleucel

    Dec 1, 2024, 00:00

  • CO91 Validation of Clinical Response Rates Extrapolated With Dose-Response Estimation Methods in Chronic Hepatitis Delta

    Dec 1, 2024, 00:00

  • HTA64 Leveraging Machine Learning for Predicting Health Technology Assessment Outcomes

    Dec 1, 2024, 00:00

  • HSD100 Economics of a Virtual Care Model for Diagnosis and Treatment of Sleep Apnea in Germany: Results From a Cost-Consequence Analysis

    Dec 1, 2024, 00:00

  • EPH230 Geographic Variation in Routine Childhood Vaccination Using Real-World Eviden Pre- and Post- COVID-19 Pandemic

    Dec 1, 2024, 00:00

  • EPH71 A Systematic Review and Meta-Analysis of Interval Cancer of Stool Testing for Colorectal Cancer Screening

    Dec 1, 2024, 00:00

  • HSD134 Prescribers' Opinions, Preferences and Attitudes on Deprescribing for Patients With Diabetes in China: A Nationwide Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • PT16 Economic Influences on Medical Decision-Making in Cancer Medicine: An Analysis of Qualitative and Quantitative Data

    Dec 1, 2024, 00:00

  • EE782 The Landscape of Pre-Exposure Prophylaxis (PrEP) in Brazil: Challenges, Advances, and Opportunities As a Public Health Strategy in the Battle Against HIV/AIDS

    Dec 1, 2024, 00:00

  • HTA69 Vaccines and EU HTA: Exploring Misalignments Between Joint Clinical Assessment Requirements and a Hypothetical Vaccine Evidence Package

    Dec 1, 2024, 00:00

  • EE691 Cost Estimation of Managing Retinitis Pigmentosa in France in a Multi-Payer Environment From a Societal Perspective

    Dec 1, 2024, 00:00

  • EE790 Cost-Effectiveness and Cost Utility Analysis of an eHealth Peer-Led Wheelchair Training Program Compared to the Existing Wheelchair Training Practice in Canadian Rehabilitation Centers: Economic Evaluation of a RCT

    Dec 1, 2024, 00:00

  • EE491 A Budget Impact Analysis of a New Treatment for Adults With Homozygous Familial Hypercholesterolaemia

    Dec 1, 2024, 00:00

  • EE836 Cost-Effectiveness of Zolbetuximab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Adenocarcinoma in Taiwan

    Dec 1, 2024, 00:00

  • HTA125 Comparison of the Joint Clinical Assessment (JCA) Dossier With the German Medicines Market Reorganization Act (AMNOG) Dossier: What Content Remains to Be Presented AMNOG Dossier After the Implementation of JCA?

    Dec 1, 2024, 00:00

  • CO56 Retrospective Non-Interventional Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients With Non-Muscle-Invasive Bladder: Real-World Experience From Six Hospital Centers in Greece

    Dec 1, 2024, 00:00

  • HPR4 Analyzing the Impact of EU5 and UK Pricing Reforms: A Pathway to Adaptation in an Evolving Policy Landscape

    Dec 1, 2024, 00:00

  • EE421 A Budget Impact Analysis of Azelastine Hydrochloride/Fluticasone Propionate (AzeFlu) Nasal Spray Suspension for Patients With Allergic Rhinitis (AR) in the Kingdom of Saudi Arabia

    Dec 1, 2024, 00:00

  • PT15 Utilization Trends and Access Disparities in CAR T-Cell Therapy: Real-World Insights From an All-Payer US Healthcare Database (2017-2024)

    Dec 1, 2024, 00:00

  • EE588 Direct Costs of RSV Cases in Hospitalized Patients (Aged ≥60 Years) Identified From 2010-2020 in a Retrospective Study in Valladolid, Spain

    Dec 1, 2024, 00:00

  • HSD33 Over a Decade of Trends in Gabapentinoid Prescribing and Daily Doses Among Patients Taking Opioids for Pain Management in Malaysia (2010-2020)

    Dec 1, 2024, 00:00

  • EE585 Increasing Conscious Sedation Use for Dental Treatments: A Cost and Consequences Analysis

    Dec 1, 2024, 00:00

  • HTA153 Health Equity Priorities for Pharmaceutical Manufacturers: Payer Perceptions From a Global Survey

    Dec 1, 2024, 00:00

  • EE439 A Multiple Myeloma Case Study for Incorporating Carbon Footprint in Health Technology Assessment

    Dec 1, 2024, 00:00

  • EE732 From Pipeline to Pricing Reimbursement: Economic Impact and Access Challenges of Upcoming Gene Therapies

    Dec 1, 2024, 00:00

  • EPH84 Burden of Hospital Candidemia in Fran Diagnostic Performance of an Administrative Hospital Database for Case Identification in a French University Hospital

    Dec 1, 2024, 00:00

  • CO79 Effectiveness of Secukinumab in Patients With Moderate to Severe Hidradenitis Suppurativa: Results From a Meta-Analysis

    Dec 1, 2024, 00:00

  • EE637 Assessment of Clinically Meaningful Benefits and Incremental Costs of Adding Bevacizumab to Trifluridine/Tipiracil for Metastatic Colorectal Cancer: A Comparison With Other Combination Regimens

    Dec 1, 2024, 00:00

  • EE386 Cost-per-Responder Analysis of Bimekizumab (IL-17A/F Inhibitor) Against Il-17A, Il-12/23 and Il-23 Inhibitors for the Treatment of Psoriatic Arthritis in Finland

    Dec 1, 2024, 00:00

  • CO37 Glucagon-like Peptide-1 Receptor Agonists for Adult Obesity: Where Next?

    Dec 1, 2024, 00:00

  • HPR13 Regional Inequity in 4CMenB Vaccination Rates in Austria Correlation With Unemployment: A Retrospective Ecological Study

    Dec 1, 2024, 00:00

  • HTA102 Are EU JCA Evidence Requirements Achievable? Insights From a Retrospective Evidence Analysis Study for Rare and Non-Rare EU Treatment Landscapes

    Dec 1, 2024, 00:00

  • EPH1 Universal Health Coverage and Education Are the Decisive Socio-Economic Disparities in Cervical Cancer Mortality in the Dominican Republic: A Multi-Dimensional Ecological Approach in a Middle-Income Caribbean Country

    Dec 1, 2024, 00:00

  • EPH32 Trends in Benzodiazepine and Z-Drug Prescribing and Long-Term Use in Hong Kong: A Descriptive Cross-Sectional Study

    Dec 1, 2024, 00:00

  • HSD57 Safety and Contagion in Inpatient Mental-Health Wards: An Estimate of the Contagion Effect From the Wardsonar Study in the UK

    Dec 1, 2024, 00:00

  • HSD90 Towards Tomorrow: Transforming Sarcoma Care in Bulgaria

    Dec 1, 2024, 00:00

  • HPR86 Frequency and Variation of Clock-Stop During EMA Assessment for Oncology Products: Implication on JCA Timelines

    Dec 1, 2024, 00:00

  • HSD138 Future Development Direction Obtained Through an Analysis of the Status and Effectiveness of Care Robots by Type: A Systematic Review

    Dec 1, 2024, 00:00

  • HPR111 Comparing Factors Influencing Price Elasticity of Pharmaceuticals and Value-Based Pricing Across Europe and the USA

    Dec 1, 2024, 00:00

  • P45 Optimizing Electronic Medical Records Data Completeness With On-Premise Artificial Intelligen A Study on Large Language Models Enhancing Medication Documentation

    Dec 1, 2024, 00:00

  • EE304 Economic Evaluation of Mailing Self-Sampling qFIT Kits to Non-Participants in Colorectal Cancer Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • EE257 Modeling the Potential Public Health Impact and Cost-Effectiveness of BNT162B2 COVID-19 Booster Vaccination in Mexico

    Dec 1, 2024, 00:00

  • EE242 Cost of Managing Brain Metastases in Patients With ALK-Positive Advanced NSCLC With First-Line ALK Tyrosine Kinase Inhibitors (TKIs) in China

    Dec 1, 2024, 00:00

  • HTA130 Key Drivers Underlying Positive and Negative Decisions for National Institute for Health and Care Excellence (NICE) Technology Appraisals (TAS) and Highly Specialised Technology (HST) Appraisals in 2023

    Dec 1, 2024, 00:00

  • CO97 Characterizing the Burden and Unmet Need of Antibody-Mediated Rejection

    Dec 1, 2024, 00:00

  • HPR161 Variation of Cost-Effectiveness Across the Population, Treatment Cost and Adoption Decision: A Case Study in CVD Prevention

    Dec 1, 2024, 00:00

  • EE662 Estimated Clinical and Economic Burden of Obesity in Japan Over the Next 5 Years

    Dec 1, 2024, 00:00

  • PT19 Emerging Trends in the Adoption of Alternative Financing Models for Advanced Therapy Medicinal Products: A Scoping Review

    Dec 1, 2024, 00:00

  • HTA170 Use of Off-Label Comparators in Health Technonology Assessment in Portugal: A Review of Reimbursement Appraisal Reports

    Dec 1, 2024, 00:00

  • HTA124 Payer Perceptions of Supportive Evidence in the Estimation of Long-Term Durability for Gene Therapies in Major European Markets

    Dec 1, 2024, 00:00

  • HTA95 Predicting Evidence Requirement Implications of the EU Joint Clinical Assessment (JCA) Through a Population, Comparator, Intervention, Outcome (PICO) Simulation for Two Anticancer Investigational Medicinal Products (IMPs)

    Dec 1, 2024, 00:00

  • EE489 Cost-Effectiveness of Zanubrutinib + Obinutuzumab for Treatment of Relapsed or Refractory Follicular Lymphoma in the United States

    Dec 1, 2024, 00:00

  • EE648 Micro-Costing Study of Comprehensive Genomic Profiling for Implementation of Precision Cancer Medicine in Public Healthcare Systems: The Norwegian Infrastructure for Precision Diagnostics and Impress-Norway Trial

    Dec 1, 2024, 00:00

  • EPH171 Factors Associated with Fracture Recurrence in Patients With Osteoporotic Fractures: A Population-Based Study in South Korea

    Dec 1, 2024, 00:00

  • CO122 Pharmacist-Driven Management of Type 2 Diabetes Improves HbA1c, Mortality, and Medical Costs in an Integrated Health System

    Dec 1, 2024, 00:00

  • HPR145 The Evolving Influence of the Inflation Reduction Act and Value Assessment in US Payer Decision-Making

    Dec 1, 2024, 00:00

  • HTA177 Reasons for Drug Market Access Failure in Portugal: A Retrospective Analysis of Public Reimbursement Reports

    Dec 1, 2024, 00:00

  • EPH252 Estimating the Size of the Brazilian Population in Supplementary Healthcare System in Secondary Prevention of Cardiovascular Disease: An Analysis of the Potential for Lipid-Lowering Treatment Beyond Statin and Ezetimibe

    Dec 1, 2024, 00:00

  • EE450 Economic Burden of People Living With HIV in China: An Analysis Based on Real-World Medical Database

    Dec 1, 2024, 00:00

  • EE354 An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US

    Dec 1, 2024, 00:00

  • EPH57 Real-World Data of Severe Viral Lower Respiratory Tract Disease; Current Landscape, Challenges, and Future Recommendations

    Dec 1, 2024, 00:00

  • HTA204 Treatment Waning in Dutch Pharmaceutical Submissions: An Exploratory Study

    Dec 1, 2024, 00:00

  • CO130 Outcomes and Economic Effects of Digital Health Services: An Umbrella Review

    Dec 1, 2024, 00:00

  • EE616 Cost of Illness Study of Inherited Retinal Diseases in the Netherlands in 2023

    Dec 1, 2024, 00:00

  • EPH285 The Influence of Health Literacy on the Selection of Healthcare Facilities: An Association Between Health Literacy Level and Number of Healthcare Facilities Visited per Patient per Year Using Real World Data in Japan

    Dec 1, 2024, 00:00

  • EE804 Cost-Effectiveness of Dupilumab in the Treatment of Moderate-to-Severe Prurigo Nodularis in France

    Dec 1, 2024, 00:00

  • EPH249 Epidemiology of Patients With Thymic Carcinoma in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • CO42 Comparison of Survival Outcomes for [177Lu]Lu-PSMA-617 vs Other Systemic Treatments in Post-Taxane Metastatic Castration-Resistant Prostate Cancer Setting: A Bayesian Network Meta-Analysis

    Dec 1, 2024, 00:00

  • PT8 Access to Orphan Medicines in Ireland

    Dec 1, 2024, 00:00

  • EPH256 Separating Fact From Fiction: Potential Use of Post-Authorization Safety Studies to Assess Safety of GLP-1s in Obesity Treatment

    Dec 1, 2024, 00:00

  • EE241 Fondaparinux: A Cost-Saving Alternative to Low-Molecular-Weight Heparins for Venous Thromboembolic Event Prevention/Treatment and Acute Coronary Syndrome Treatment

    Dec 1, 2024, 00:00

  • HSD54 Epidemiology, Healthcare Resource Utilization, and Costs of Hemophilia A and B by Treatment Regimen: A Retrospective Claims Data Analysis in Germany From 2016 to 2021

    Dec 1, 2024, 00:00

  • EPH63 Prevalence and Risks of Mental Health Issues During the Postnatal Period

    Dec 1, 2024, 00:00

  • EE763 Indirect Costs in 5 Types of Cancer in Adults in Mexico From 2024 to 2030

    Dec 1, 2024, 00:00

  • HPR250 Reimbursement Decisions for Innovative Drug Technologies in Poland: Duration of Reimbursement Processes and Impact of HTA Recommendation

    Dec 1, 2024, 00:00

  • EPH176 Controlling RSV in Older Adults: Clinical Benefits of a Dutch Vaccination Program

    Dec 1, 2024, 00:00

  • HTA34 How Can the Marketing Authorization Holders Be Ready for the Implementation of the Joint Clinical Assessments in 2025?

    Dec 1, 2024, 00:00

  • HTA75 Payer Perceptions of Health Inequalities in Reimbursement Decision-Making: Results of a Global Survey

    Dec 1, 2024, 00:00

  • Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study [Editor's Choice]

    Dec 1, 2024, 00:00

  • CO71 HTA Assessment of Quality of Survival Via Patient-Relevant Endpoints in Prostate Cancer

    Dec 1, 2024, 00:00

  • HPR222 European Reimbursement Process Overview of Digital Medical Device

    Dec 1, 2024, 00:00

  • HSD4 Management of Guillain-Barré Syndrome: A Systematic Review of Clinical Practice Guidelines

    Dec 1, 2024, 00:00

  • HTA101 Inequities in COPD Treatment Access Across Brazilian Municipalities: A Population-Based Analysis

    Dec 1, 2024, 00:00

  • HPR16 Performance Indicators for the Assessment of Ageing-in-Place Reform Policies: A Scoping Review and Evidence Map

    Dec 1, 2024, 00:00

  • EE692 Uncovering the Blind Spot: A Targeted Search of Placebo Effect Adjustments in Submissions to the National Institute for Health and Care Excellence

    Dec 1, 2024, 00:00

  • EPH119 RSV-Passive Immunization Reduces Antimicrobial Consumption During RSV Infection in Infants and Young Children 5 Years in Japan

    Dec 1, 2024, 00:00

  • EPH53 The Indirect Costs Related to HPV-Attributable Cancer Mortality in European Countries; Years of Life Lost, and Productivity Costs

    Dec 1, 2024, 00:00

  • EE672 Optimizing Costs and Sustainability for Gamma Knife Radiosurgery: A Cost and Breakeven Analysis at India's Largest Neurosurgery Centre

    Dec 1, 2024, 00:00

  • HPR217 Analysis of Public Health Insurance Expenditures in Türkiye by Social Security Institution Between 2020 and 2023

    Dec 1, 2024, 00:00

  • EE398 Direct and Indirect Benefits of Clinical Trials for the Public Health Care: Finnish Society Gains 10 Million Euros of Value Per Trial

    Dec 1, 2024, 00:00

  • HTA100 How Do Abbreviated HTA Submissions Impact Reimbursement? A SMC Case Study

    Dec 1, 2024, 00:00

  • HSD124 Application of Diagnosis-Related Group (DRG) in Measuring the Impact of Clinical Pathway on Resource Utilization for Patients Suspected With Acute Coronary Syndrome in the Emergency Department

    Dec 1, 2024, 00:00

  • EE793 An Early Economic Evaluation to Identify the Necessary Test Characteristics of Novel Biomarker Tests for Giant Cell Arteritis

    Dec 1, 2024, 00:00

  • EE629 Estimating the Carbon Intensity Profile of a Biologic for the Treatment of Chronic Obstructive Pulmonary Disease in the United Kingdom

    Dec 1, 2024, 00:00

  • EE786 QoL Data in CAR-T Cost-Effectiveness Analysis (CEA) in Fran What to Use?

    Dec 1, 2024, 00:00

  • EPH92 The Last of Fungus? Recent Developments in Fungal Infections in the German Hospital Setting

    Dec 1, 2024, 00:00

  • CO15 Real-World Treatment Usage of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Belgium: Results of the AREVEDECY Study

    Dec 1, 2024, 00:00

  • HTA39 Using Environmental Impact Data to Support Health Technology Assessment at NICE: An Options Appraisal

    Dec 1, 2024, 00:00

  • HSD104 Care Integration With Telemedicine for Remote Monitoring of Pressure Ulcers in Home Care Patients

    Dec 1, 2024, 00:00

  • EE797 Health Care Resource Use Associated With Respiratory Syncytial Virus Infection in Infants and Young Children in Germany: Evidence From the PAPI Study

    Dec 1, 2024, 00:00

  • EPH284 Exploring the Association Between Health Literacy and Depression Prevalence Through Personal Health Record Associated With Health Insurance Claims Data

    Dec 1, 2024, 00:00

  • EPH121 Minimum Legal Age of Tobacco Sales Law as a Commitment Mechanism: A Regression Discontinuity Design

    Dec 1, 2024, 00:00

  • EE604 A Multi-State Model to Assess the Impact of Ruxolitinib in Extending Failure Free Survival and Life Expectancy in Patients With Steroid-Refractory Acute Graft vs Host Disease

    Dec 1, 2024, 00:00

  • EE417 Quantifying the Value of Aztreonam-Avibactam in Treating Suspected Metallo-Beta-Lactamase Producing Enterobacterales Infections in Gree A STEDI Value Approach

    Dec 1, 2024, 00:00

  • P60 Socioeconomic Burden of Major Diseases in Eight Latin American Countries

    Dec 1, 2024, 00:00

  • EE622 Direct Healthcare Costs of Incident Heart Failure After Acute Coronary Syndrome

    Dec 1, 2024, 00:00

  • EE548 Cost-Effectiveness Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • EPH220 Payer-Reported Patient Burden for Hematopoietic Cell Transplantation (HCT) in the United States

    Dec 1, 2024, 00:00

  • HSD121 Change in Metabolic Syndrome of the Primary Care-Based National Lifestyle Intervention Program: An Observation Cohort Study

    Dec 1, 2024, 00:00

  • HTA82 A Blueprint for Success: The Importance of Multi-Stakeholder Alignment for EU Health Technology Assessment (HTA)

    Dec 1, 2024, 00:00

  • HPR233 Impacts of National Volume-Based Procurement Policy on Prices of Non-Winning Drugs in China: An Interrupted Time Series

    Dec 1, 2024, 00:00

  • EE357 Estimating Health State Utilities in LGMD 2E/R4, 2D/R3, and 2C/R5: Analysis of EQ-5D Baseline Data From the JOURNEY Natural History Study

    Dec 1, 2024, 00:00

  • Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism [Editor's Choice]

    Dec 1, 2024, 00:00

  • HTA10 HTA Considerations for Large Language Models in Healthcare

    Dec 1, 2024, 00:00

  • HPR64 Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review

    Dec 1, 2024, 00:00

  • CO51 Second-Line Pharmacological Interventions for Advanced Non-Small Cell Lung Cancer in MetEX14 Skipping Patients: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EPH167 Trends in Epidemiology and Mortality of Patients With Hypertension in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • HPR26 Managed Entry Agreements to Mitigate Uncertainties and Reimbursement Challenges for Orphan Drugs: A Matrix to Determine Their Suitability

    Dec 1, 2024, 00:00

  • HSD63 Use of Resources and Cost in the Management of Gastrointestinal Bleeding Associated With Direct Oral Anticoagulants or Warfarin

    Dec 1, 2024, 00:00

  • EE833 Economic Burden of Atherosclerotic Cardiovascular Disease in France in 2021: Results From the French Nationwide Claims Database (SNDS)

    Dec 1, 2024, 00:00

  • EE390 Potential Budget Impact of Using a Cyanoacrylate Polymer Barrier Film Compared to Traditional Methods for the Management of Incontinence-Associated Dermatitis for Residents of a Skilled Nursing Facility

    Dec 1, 2024, 00:00

  • HPR79 The Turning Point of Substance Use Among Disadvantaged Young People in England: A Mediation Analysis

    Dec 1, 2024, 00:00

  • P8 Assessment of CO2 Equivalent Emissions in Effective Type 2 Diabetes Management: An Economic Modelling Study

    Dec 1, 2024, 00:00

  • HTA215 Targeted Review: Generalizability of Clinical Trial Evidence to the Patient Population in NICE Technology Appraisals

    Dec 1, 2024, 00:00

  • EE247 Fully Replicating Published Markov Health Economic Models Using Generative AI

    Dec 1, 2024, 00:00

  • HTA143 A Review on the Role of Comparators in French Health Technology Assessments

    Dec 1, 2024, 00:00

  • HSD18 Exploration of the Perception on Physical Activity and Its Correlation With Patients' Quality of Life at Vironas Health Center

    Dec 1, 2024, 00:00

  • HSD10 Reimbursement of Remote Health Services in Turkiye

    Dec 1, 2024, 00:00

  • HSD40 Therapeutic Decision-Making for Patients With Sickle Cell Disease (SCD) and How Research Findings Influence the Potential Use of Mitapivat

    Dec 1, 2024, 00:00
  • «
  • 11
  • 12
  • 13 (current)
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • »